The NIH is starting a clinical trial to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines.
- Investigators will examine the biological mechanism behind the reactions and whether a genetic pattern or other factors can predict who is at most risk
- The Phase 2 trial, called Systemic Allergic Reactions to SARS-CoV-2 Vaccination, is sponsored and funded by NIAID
- The study team will enroll 3,400 adults ages 18 to 69 years at up to 35 academic allergy-research centers nationwide
- NOTE: ...